PL362965A1 - Zastosowanie profilaktyczne i terapeutyczne oltiprazu jako środka przeciwko zwłóknieniu i marskościwątroby oraz kompozycja farmaceutyczna zawierająca oltipraz - Google Patents

Zastosowanie profilaktyczne i terapeutyczne oltiprazu jako środka przeciwko zwłóknieniu i marskościwątroby oraz kompozycja farmaceutyczna zawierająca oltipraz

Info

Publication number
PL362965A1
PL362965A1 PL01362965A PL36296501A PL362965A1 PL 362965 A1 PL362965 A1 PL 362965A1 PL 01362965 A PL01362965 A PL 01362965A PL 36296501 A PL36296501 A PL 36296501A PL 362965 A1 PL362965 A1 PL 362965A1
Authority
PL
Poland
Prior art keywords
oltipraz
anticirrhotic
antifibrotic
prophylactic
liver
Prior art date
Application number
PL01362965A
Other languages
English (en)
Inventor
Sang-Geon Kim
Keon-Wook Kang
Original Assignee
Sang-Geon Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang-Geon Kim filed Critical Sang-Geon Kim
Publication of PL362965A1 publication Critical patent/PL362965A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL01362965A 2000-04-07 2001-03-02 Zastosowanie profilaktyczne i terapeutyczne oltiprazu jako środka przeciwko zwłóknieniu i marskościwątroby oraz kompozycja farmaceutyczna zawierająca oltipraz PL362965A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20000018134 2000-04-07

Publications (1)

Publication Number Publication Date
PL362965A1 true PL362965A1 (pl) 2004-11-02

Family

ID=19662428

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01362965A PL362965A1 (pl) 2000-04-07 2001-03-02 Zastosowanie profilaktyczne i terapeutyczne oltiprazu jako środka przeciwko zwłóknieniu i marskościwątroby oraz kompozycja farmaceutyczna zawierająca oltipraz

Country Status (16)

Country Link
US (1) US20030191137A1 (pl)
EP (1) EP1292309A4 (pl)
JP (1) JP2003530353A (pl)
KR (1) KR100404303B1 (pl)
CN (1) CN1192775C (pl)
AU (1) AU780161B2 (pl)
BR (1) BR0109747A (pl)
CA (1) CA2404915A1 (pl)
HU (1) HUP0300221A3 (pl)
MX (1) MXPA02009695A (pl)
NO (1) NO20024724L (pl)
NZ (1) NZ521710A (pl)
PL (1) PL362965A1 (pl)
RU (1) RU2258509C2 (pl)
WO (1) WO2001076604A1 (pl)
ZA (1) ZA200207867B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078045B2 (en) 2000-03-02 2006-07-18 Sang-Geon Kim Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
KR100491318B1 (ko) * 2002-11-26 2005-05-24 씨제이 주식회사 올티프라즈(Ｏｌｔｉｐｒａｚ) 제조방법
KR100476069B1 (ko) * 2003-02-12 2005-03-10 주식회사 태평양 １，２－디티올티온 유도체를 함유하는 발모촉진용 또는탈모방지용 조성물
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR100590818B1 (ko) 2004-10-11 2006-06-19 재단법인서울대학교산학협력재단 소분자 유기화합물의 직접적 ｐ90 리보솜 Ｓ6 키나제 1(ＲＳＫ1)의 활성증진에 의한 당뇨병, 비만 및대사증후군의 예방 및 치료용도
KR20060031956A (ko) * 2004-10-11 2006-04-14 재단법인서울대학교산학협력재단 ｐ90 리보솜 Ｓ6 키나제 1 (ＲＳＫ1)의 직접적인 키나제활성증진을 통한 간섬유화와 간경변증 예방 및 치료용약학조성물
KR100604261B1 (ko) 2004-10-11 2006-07-28 재단법인서울대학교산학협력재단 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물
CA2651623A1 (en) * 2006-05-11 2007-11-22 Patrick T. Prendergast Compositions and methods for modulating the immune system
KR101057485B1 (ko) * 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
MX386503B (es) * 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US20160376259A1 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for Preparing Oltipraz
US11364239B2 (en) 2020-04-29 2022-06-21 Cfd Research Corporation Compositions and methods for mitigating aflatoxin B1-induced liver injury
CN112546216B (zh) * 2020-11-20 2022-10-28 西湖大学 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794873A (fr) * 1972-02-02 1973-08-01 Rhone Poulenc Sa Nouvelles sulfones a enchainement dimethyl-1,6 hexadien-1,5 ylene
DE2505869C3 (de) * 1975-02-12 1978-05-18 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von symmetrischen Carotinoiden
JPS54160740A (en) * 1978-06-09 1979-12-19 Takeda Chem Ind Ltd Anti-fibrotic agent
US4883887A (en) * 1987-07-09 1989-11-28 Hoffmann-La Roche Inc. Sulfone polyene intermediates
US6517824B1 (en) * 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
KR0138005B1 (ko) * 1993-10-21 1998-05-15 김낙두 신규의 화학적 보호제(chemopreventive agent)및 그의 제조방법
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
AU5620598A (en) * 1996-12-31 1998-07-31 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
US6294350B1 (en) * 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
KR100261139B1 (ko) * 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
US6242478B1 (en) * 1999-12-10 2001-06-05 Wake Forest University Five member ring sulfenate esters and thiosulfinate esters
RU2219935C1 (ru) * 2002-07-09 2003-12-27 НИИ онкологии им. проф. Н.Н. Петрова Средство для профилактики рака

Also Published As

Publication number Publication date
EP1292309A1 (en) 2003-03-19
CN1420772A (zh) 2003-05-28
HUP0300221A3 (en) 2003-09-29
AU3776701A (en) 2001-10-23
NZ521710A (en) 2004-06-25
NO20024724L (no) 2002-11-29
RU2002129873A (ru) 2004-03-27
CA2404915A1 (en) 2001-10-18
AU780161B2 (en) 2005-03-03
JP2003530353A (ja) 2003-10-14
KR100404303B1 (ko) 2003-11-03
MXPA02009695A (es) 2003-03-27
NO20024724D0 (no) 2002-10-02
RU2258509C2 (ru) 2005-08-20
HUP0300221A2 (hu) 2003-07-28
KR20010091012A (ko) 2001-10-22
EP1292309A4 (en) 2004-08-11
US20030191137A1 (en) 2003-10-09
WO2001076604A1 (en) 2001-10-18
ZA200207867B (en) 2003-08-01
BR0109747A (pt) 2003-02-04
CN1192775C (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
HUP0302550A3 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines and pharmaceutical compositions containing them
HUP0301452A3 (en) Pharmaceutical composition containing photochemotherapeutic agent and mucoadhesive agent and its use
AU3104301A (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
IL163278A (en) Formulations including glp-1 compounds and their use in drug preparation
HUP0203588A3 (en) Analgesic pharmaceutical compositions and their use
EG24408A (en) Low dose entecavir formulation and use
SI1329456T1 (sl) Glukopiranoziloksibenzilbenzenski derivati in zdravilni sestavki, ki vsebujejo te spojine
IL156558A0 (en) Novel quinuclidine derivatives and medicinal compositions containing the same
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
HUP0300382A3 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
HUP0400384A3 (en) Benzamidine derivative and pharmaceutical compositions containing them and their use
HUP0300798A3 (en) Substituted-triazolopyrimidines and their use as anticancer agents and pharmaceutical compositions containing them
AU7645701A (en) Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides
PL362965A1 (pl) Zastosowanie profilaktyczne i terapeutyczne oltiprazu jako środka przeciwko zwłóknieniu i marskościwątroby oraz kompozycja farmaceutyczna zawierająca oltipraz
HUP0202862A3 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
IL152846A0 (en) Pyridazinone derivatives and pharmaceutical compositions containing the same
AU4303600A (en) Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate
AU2002361060A8 (en) Use of apple core extracts in cosmetic or pharmaceutical compositions
AU2003260241A1 (en) Buguzhi agent and composition and methods of preparing and administering the same
HUP0401484A3 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine and pharmaceutical compositions containing the combination
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
IL153487A0 (en) Pharmaceutical compositions and methods for use
AU5587800A (en) S-(+)-desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)